{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:46:25Z","timestamp":1792633585568,"version":"4.5.0"},"reference-count":65,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T00:00:00Z","timestamp":1437955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxics"],"abstract":"<jats:p>The boronic acid dipeptide bortezomib, able to induce tumor cell death by degradation of key proteins, is the first proteasome inhibitor drug to enter clinical practice. It is employed as first-line treatment in relapsed or resistant multiple myeloma (MM) patients. However, bortezomib often induces a dose-limiting toxicity in the form of painful sensory neuropathy, which can mainly be reduced by subcutaneous administration or dose modification. In this review we focus on the current understanding of the pathophysiological mechanisms  of bortezomib-induced neuropathy to allow further studies in animal models and  humans, including analysis of clinical and pharmacogenetic aspects, to optimize the  treatment regimens.<\/jats:p>","DOI":"10.3390\/toxics3030294","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T02:12:37Z","timestamp":1438049557000},"page":"294-303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["An Overview of Bortezomib-Induced Neurotoxicity"],"prefix":"10.3390","volume":"3","author":[{"given":"Cristina","family":"Meregalli","sequence":"first","affiliation":[{"name":"Experimental Neurology Unit, Department of Surgery and Translational Medicine, University of  Milan-Bicocca, Via Cadore 48, 20900 Monza (MB), Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1158\/0008-5472.CAN-05-0506","article-title":"Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells","volume":"65","author":"Altun","year":"2005","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: A phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ajh.23810","article-title":"Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management","volume":"89","author":"Rajkumar","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1586\/17474086.2014.899144","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"7","author":"Grosicki","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Mai, E.K., Bertsch, U., D\u00fcrig, J., Kunz, C., Haenel, M., Blau, I.W., Munder, M., Jauch, A., Schurich, B., and Hielscher, T. (2015). Phase III trial of bortezomib, cyclophosphamide, dexamethasone (VCD) versus bortezomib, doxorubicin, dexamethasone (PAd) in newly-diagnosed myeloma. Leukemia.","DOI":"10.1038\/leu.2015.80"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.drup.2008.08.002","article-title":"Mechanisms of proteasome inhibitor action and resistance in cancer","volume":"11","author":"McConkey","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/07853890410030877","article-title":"Proteasome inhibition in hematologic malignancies","volume":"36","author":"Richardson","year":"2004","journal-title":"Ann. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10286-012-0164-8","article-title":"Bortezomib-induced severe autonomic neuropathy","volume":"2","author":"Stratogianni","year":"2012","journal-title":"Clin. Auton. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_13","first-page":"18","article-title":"Chemotherapy-induced neurotoxicity: The value of neuroprotective strategies","volume":"7","author":"Beijers","year":"2012","journal-title":"Neth. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"26","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: Efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"20","author":"Richardson","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3109\/10428194.2010.483303","article-title":"Peripheral neuropathy during bortezomib treatment of multiple myeloma: A review of recent studies","volume":"51","author":"Cavaletti","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","first-page":"421","article-title":"Bortezomib-induced painful neuropathy in patients with multiple myeloma","volume":"17","year":"2013","journal-title":"Contemp. Oncol. (Pozn.)"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1529-8027.2008.00192.x","article-title":"Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity","volume":"13","author":"Lanzani","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1529-8027.2011.00346.x","article-title":"Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model","volume":"1","author":"Bruna","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00520-014-2256-6","article-title":"Impact of dose modification on intravenous bortezomib-induced peripheral neuropathy in multiple myeloma patients","volume":"22","author":"Cho","year":"2014","journal-title":"Support. Care Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3324\/haematol.13285","article-title":"Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma","volume":"93","author":"Moreau","year":"2008","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf","year":"2012","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: An update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FPC.0b013e3283436b45","article-title":"Genetic variation associated with bortezomib-induced peripheral neuropathy","volume":"21","author":"Favis","year":"2011","journal-title":"Pharmacogenet. Genomics."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3324\/haematol.2011.041434","article-title":"Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients","volume":"9","author":"Corthals","year":"2011","journal-title":"Haematologica"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: A prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"1","author":"Broyl","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jpain.2006.09.014","article-title":"Quantitative sensory findings in patients with bortezomib-induced pain","volume":"8","author":"Cata","year":"2007","journal-title":"J. Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1182\/blood-2008-04-149385","article-title":"Bortezomib-induced peripheral neuropathy in multiple myeloma: A comprehensive review of the literature","volume":"112","author":"Argyriou","year":"2008","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.3324\/haematol.11752","article-title":"Bortezomib-induced peripheral neurotoxicity: Still far from a painless gain","volume":"92","author":"Cavaletti","year":"2007","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.clinph.2008.08.007","article-title":"Immune-mediated neuropathies in myeloma patients treated with bortezomib","volume":"119","author":"Ravaglia","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuro.2011.10.010","article-title":"Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy","volume":"33","author":"Gilardini","year":"2012","journal-title":"Neurotoxicology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.4161\/cc.27476","article-title":"Evaluation of tubulin polymerization and chronic inhibition of proteasome as citotoxicity mechanisms in bortezomib-induced peripheral neuropathy","volume":"13","author":"Meregalli","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: A neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: A behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur. J. Pain"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.expneurol.2010.09.004","article-title":"Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies","volume":"226","author":"Carozzi","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp. Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.expneurol.2006.05.007","article-title":"Paclitaxel- and vincristine-evoked painful peripheral neuropathies: Loss of epidermal innervation and activation of Langerhans cells","volume":"201","author":"Siau","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ene.12353","article-title":"Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies","volume":"21","author":"Qvortrup","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12640-009-9086-1","article-title":"Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons","volume":"17","author":"Casafont","year":"2010","journal-title":"Neurotox. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1007\/s00018-013-1474-2","article-title":"Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons","volume":"71","author":"Palanca","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_42","first-page":"430","article-title":"Toxic effects of bortezomib on primary sensory neurons and schwann cells of adult mice","volume":"2","author":"Bruna","year":"2015","journal-title":"Neurotox. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4161\/cc.7.7.5625","article-title":"Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition","volume":"7","author":"Poruchynsky","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.neuro.2013.09.001","article-title":"Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons","volume":"39","author":"Staff","year":"2013","journal-title":"Neurotoxicology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-04-3684","article-title":"Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341\/bortezomib) cytotoxicity in myeloma cell lines","volume":"65","author":"Landowski","year":"2005","journal-title":"Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1213\/01.ane.0000204318.35194.ed","article-title":"Dysregulation of cellular calcium homeostasis in chemotherapy-evoked painful peripheral neuropathy","volume":"102","author":"Siau","year":"2006","journal-title":"Anesth. Analg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp. Neurol."},{"key":"ref_48","first-page":"107","article-title":"Study on mechanism of bortezomib inducing peripheral neuropathy and the reversing effect of reduced glutathione","volume":"32","author":"Wang","year":"2011","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","article-title":"The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status","volume":"107","author":"Villamor","year":"2006","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.yexcr.2004.02.001","article-title":"The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib","volume":"295","author":"Yu","year":"2004","journal-title":"Exp. Cell Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"33714","DOI":"10.1074\/jbc.M302559200","article-title":"Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells","volume":"278","author":"Ling","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s12094-006-0176-8","article-title":"The proteasome: A novel target for anticancer therapy","volume":"8","author":"Montagut","year":"2006","journal-title":"Clin. Transl. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","article-title":"Regulation mechanisms and signaling pathways of autophagy","volume":"43","author":"He","year":"2009","journal-title":"Annu. Rev. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1158\/0008-5472.CAN-12-4370","article-title":"Novel therapeutic strategy to prevent chemotherapy-induced persistent sensory neuropathy byTRPA1 blockade","volume":"73","author":"Trevisan","year":"2013","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1365-2141.2010.08138.x","article-title":"Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain","volume":"149","author":"Mangiacavalli","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_56","first-page":"5453","article-title":"Antibody against tumor necrosis factor-\u03b1 reduces bortezomib-induced allodynia in a rat model","volume":"33","author":"Chiorazzi","year":"2013","journal-title":"Anticancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3923\/pjbs.2010.577.587","article-title":"Role of erythropoeitin in prevention of chemotherapy-induced peripheral neuropathy","volume":"13","author":"Kassem","year":"2010","journal-title":"Pak. J. Biol. Sci."},{"key":"ref_58","first-page":"517","article-title":"Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B","volume":"3","author":"Ceresa","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11940-010-0108-3","article-title":"Chemotherapy-induced neuropathy","volume":"13","author":"Cavaletti","year":"2011","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2146\/ajhp130126","article-title":"Prevention and treatment of chemotherapy-induced peripheral neuropathy","volume":"71","author":"Piccolo","year":"2014","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.pain.2013.07.032","article-title":"Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase","volume":"154","author":"Janes","year":"2013","journal-title":"Pain"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.expneurol.2013.12.020","article-title":"Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model","volume":"253","author":"Bruna","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/JBM.S44127","article-title":"The protective effects of lafutidine for bortezomib induced peripheral neuropathy","volume":"4","author":"Tsukaguchi","year":"2013","journal-title":"J. Blood Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s12185-011-0850-7","article-title":"Delayed treatment with vitamin C and N-acetyl-l-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib","volume":"93","author":"Nakano","year":"2011","journal-title":"Int. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial","volume":"3","author":"Smith","year":"2013","journal-title":"JAMA"}],"container-title":["Toxics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2305-6304\/3\/3\/294\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:49:47Z","timestamp":1760215787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2305-6304\/3\/3\/294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,27]]},"references-count":65,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["toxics3030294"],"URL":"https:\/\/doi.org\/10.3390\/toxics3030294","relation":{},"ISSN":["2305-6304"],"issn-type":[{"value":"2305-6304","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,27]]}}}